Biomedical Engineering Reference
In-Depth Information
[5] The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary
Medicinal Products (CPMP): Note for Guidance on Parametric Release (CPMP/QWP/3015/
99). 2001. (http://www.emea.europa.eu/pdfs/human/qwp/301599en.pdf )
[6] Kelly BD. Establishing process robustness using designed experiments. In: Sofer Gail,
Zabriskie Dane W, editors. Biopharmaceutical Process Validation. New York: Marcel
Dekker, Inc.; 2000. p 29-59.
[7] Anderson AJ, Whitcomb PJ. DOE Simplified: Practical Tools for Effective Experimentation.
Portland, OR: Productivity Press; 2000.
[8] U.S. Food and Drug Administration. Guidance for Industry: Q9 Quality Risk Assessment.
2006. (http://www.fda.gov/cber/gdlns/ichq9risk.htm)
[9] Parenteral Drug Association. PDA Technical Report 42. Process validation of protein
manufacturing. PDA J Pharm Sci Technol 2005;59(S-4):1-28.
[10] Gardner AR, Smith TM. Identification and establishment of operating ranges of critical
variables. In: Sofer Gail, Zabriskie DaneW. editors. Biopharmaceutical Process Validation.
New York: Marcel Dekker, Inc; 2000. p 61-76.
[11] Rathore AS, Krishnan R, Tozer S, Smiley D, Rausch S, Seely J. Scaling down of
biopharmaceutical unit operations—part 2: chromatography and filtration. Biopharm Int
2005;18(4):58-64.
[12] Godavarti R, Petrone J, Robinson J, Wright R, Kelley BD. Scaled-down models for
purification processes: approaches and applications. In: Rathore AS, Sofer G, editors.
Process Validation in Manufacturing of Biopharmaceuticals. Boca Raton, FL: Taylor &
Francis; 2005. p 69-142.
[13] Darling AJ. Validation of the purification process for viral clearance evaluation. In: Sofer
Gail, Zabriskie DaneW, editors. Biopharmaceutical Process Validation. NewYork: Marcel
Dekker, Inc; 2000. p 157-196.
[14] U.S. Food and Drug Administration. Guidance for Industry: Q5AViral Safety Evaluation of
Biotechnology Products Derived FromCell Lines of Human or Animal Origin. 1998. (http://
www.gda/gov/cder/Guidance/Q5A-fnl.PDF)
[15] Romero, JK, Chrostowski, J, Vilmorin P. US PATENT (P0697 US 001—Prov. Appl. 60/
855,734). Method for Isolating Biomacromolecules Using Low pH and Divalent Cations.
U.S. Patent and Trademark Office, November 2, 2006.
[16] Romero, J, Chrostowski, J, Vilmorin, P Case, J. Effects of pH and ionic conditions on
microfiltration of mammalian cells: combined permeate flux enhancement and mAb
purification capabilities. American Institute of Chemical Engineering annual meeting, San
Francisco, CA; 2006.
[17] Birch JR, Racher AJ. Antibody production. Adv Drug Deliv Rev 2006;58:671-685.
[18] Finette GMS, Mao QM, Hearn MTW. Comparative studies on the isothermal characteristics
of proteins adsorbed under batch equilibrium conditions to ion-exchange, immobilised metal
ion affinity and dye affinitymatrices with different ionic strength and temperature conditions.
J Chromatogr A 1997;763:71-90.
